Lexicon Pharmaceuticals (NASDAQ:LXRX)‘s stock had its “buy” rating reaffirmed by stock analysts at Wedbush in a research report issued on Monday, TipRanks reports. They presently have a $17.00 price target on the biopharmaceutical company’s stock. Wedbush’s price target would indicate a potential upside of 437.97% from the stock’s current price.

LXRX has been the subject of a number of other reports. ValuEngine upgraded shares of Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. Gabelli upgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Wednesday, September 11th. Zacks Investment Research cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 16th. Citigroup cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and lifted their target price for the company from $3.00 to $4.00 in a research note on Friday, November 8th. Finally, G.Research upgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the stock. Lexicon Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $6.45.

Shares of LXRX stock traded down $0.37 during trading on Monday, hitting $3.16. 3,109,121 shares of the company were exchanged, compared to its average volume of 1,293,999. The company has a debt-to-equity ratio of 1.42, a quick ratio of 8.01 and a current ratio of 8.11. The firm has a market capitalization of $375.14 million, a price-to-earnings ratio of -2.77 and a beta of 1.00. The business’s 50-day simple moving average is $3.62 and its 200 day simple moving average is $3.95. Lexicon Pharmaceuticals has a twelve month low of $1.13 and a twelve month high of $8.39.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.31 by $0.80. The firm had revenue of $294.45 million during the quarter, compared to analysts’ expectations of $12.00 million. Lexicon Pharmaceuticals had a net margin of 49.78% and a return on equity of 2,372.40%. The company’s revenue was up 4124.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.26) earnings per share. On average, equities analysts forecast that Lexicon Pharmaceuticals will post 0.93 earnings per share for the current fiscal year.

In other news, CEO Lonnel Coats acquired 50,000 shares of Lexicon Pharmaceuticals stock in a transaction dated Tuesday, September 17th. The stock was acquired at an average cost of $3.13 per share, for a total transaction of $156,500.00. Following the completion of the purchase, the chief executive officer now owns 127,639 shares of the company’s stock, valued at $399,510.07. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Christopher J. Sobecki acquired 25,000 shares of Lexicon Pharmaceuticals stock in a transaction dated Monday, September 16th. The stock was purchased at an average price of $2.55 per share, with a total value of $63,750.00. Following the completion of the purchase, the director now directly owns 112,493 shares of the company’s stock, valued at approximately $286,857.15. The disclosure for this purchase can be found here. Insiders acquired 178,749 shares of company stock valued at $474,560 over the last quarter. Corporate insiders own 6.40% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Commonwealth Equity Services LLC lifted its stake in shares of Lexicon Pharmaceuticals by 40.5% in the third quarter. Commonwealth Equity Services LLC now owns 16,461 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 4,746 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of Lexicon Pharmaceuticals in the second quarter worth $92,000. Voloridge Investment Management LLC acquired a new stake in shares of Lexicon Pharmaceuticals in the second quarter worth $105,000. Quantitative Systematic Strategies LLC lifted its stake in shares of Lexicon Pharmaceuticals by 67.2% in the second quarter. Quantitative Systematic Strategies LLC now owns 20,648 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 8,302 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Lexicon Pharmaceuticals in the third quarter worth $202,000. Institutional investors and hedge funds own 96.27% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Story: How interest rates affect municipal bond prices

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.